Please enable JavaScript to continue using this application.

Compare $GANX vs $RNTX | Chartloom

Compare

$GANX vs $RNTX

Gain Therapeutics Inc · Rein Therapeutics Inc

GANX

Gain Therapeutics Inc

RNTX

Rein Therapeutics Inc

Compare $GANX vs $RNTX

Comparing Gain Therapeutics Inc and Rein Therapeutics Inc

GANXGain Therapeutics Inc

RNTXRein Therapeutics Inc

GANXGain Therapeutics Inc

Market cap

$70M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-48.4%

52W performance

-20.8%

FCF yield

-27.1%

RNTXRein Therapeutics Inc

Market cap

$68M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-36.5%

52W performance

-42.9%

FCF yield

-27.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GANX

RNTX

Detailed metrics comparison

GANX

Gain Therapeutics Inc

RNTX

Rein Therapeutics Inc

Market Cap

GANX$70M

RNTX$68M

Enterprise Value

GANX$57M

RNTX$59M

Price

GANX$1.64

RNTX$0.79

P/E Ratio

GANXN/A

RNTXN/A

P/S Ratio

GANX466.44x

RNTX0.00x

EV/Sales

GANX386.81x

RNTX0.00x

EV/EBITDA

GANX0.00x

RNTX0.00x

P/B Ratio

GANX6.61x

RNTX1.25x

P/FCF Ratio

GANXN/A

RNTXN/A

EV/FCF

GANX-3.02x

RNTX-3.15x

PEG Ratio

GANXN/A

RNTXN/A

Forward P/E (NTM)

GANXN/A

RNTXN/A

Forward P/S (NTM)

GANXN/A

RNTXN/A

Revenue (TTM)

GANX$0

RNTX$0

Revenue Growth (YoY)

GANXN/A

RNTXN/A

Forward Rev Growth

GANX180.0%

RNTX113.7%

Gross Margin (TTM)

GANX0.0%

RNTX0.0%

Operating Margin (TTM)

GANX0.0%

RNTX0.0%

EBITDA Margin (TTM)

GANX0.0%

RNTX0.0%

Net Margin (TTM)

GANX0.0%

RNTX0.0%

FCF Margin (TTM)

GANXN/A

RNTXN/A

Net Income (TTM)

GANX$-20M

RNTX$-50M

FCF (TTM)

GANX$-19M

RNTX$-19M

EPS (TTM)

GANX-$0.47

RNTX-$0.74

ROE (TTM)

GANX-16158.0%

RNTX-15323.0%

ROA (TTM)

GANX-11836.0%

RNTX-11700.0%

ROIC (TTM)

GANX-15673.0%

RNTX-14763.0%

Cash

GANX$13M

RNTX$9M

Debt

GANX$344K

RNTX$0

Net Cash/Debt

GANX$13M

RNTX$9M

Current Ratio (TTM)

GANX4.36x

RNTX4.27x

Quick Ratio (TTM)

GANX4.11x

RNTX4.26x

Debt/Equity (TTM)

GANX0.03x

RNTX0.00x

Debt/Assets (TTM)

GANX0.0%

RNTX0.0%

Interest Coverage (TTM)

GANXN/A

RNTXN/A

Net Debt/EBITDA (TTM)

GANX0.00x

RNTX0.00x

Beta

GANX0.21

RNTX1.40

52W Performance

GANX-20.8%

RNTX-42.9%

YTD Performance

GANX-48.4%

RNTX-36.5%

% from 52W High

GANX-62.2%

RNTX-63.6%

% from 52W Low

GANX7.2%

RNTX14.4%

Asset Turnover (TTM)

GANX0.01x

RNTX0.00x

FCF Yield (TTM)

GANX-27.1%

RNTX-27.7%

Earnings Yield (TTM)

GANX-28.7%

RNTX-73.3%

Dividend Yield (TTM)

GANXN/A

RNTXN/A

Rule of 40

GANX0.0

RNTX0.0

EV/GP/RG

GANXN/A

RNTXN/A

Ticker research

View GANX research View RNTX research

Metric	GANX Gain Therapeutics Inc	RNTX Rein Therapeutics Inc
Market & Valuation
Market Cap	$70M	$68M
Enterprise Value	$57M	$59M
Price	$1.64	$0.79
P/E Ratio	N/A	N/A
P/S Ratio	466.44x	0.00x
EV/Sales	386.81x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.61x	1.25x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.02x	-3.15x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	180.0%	113.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-20M	$-50M
FCF (TTM)	$-19M	$-19M
EPS (TTM)	-$0.47	-$0.74
ROE (TTM)	-16158.0%	-15323.0%
ROA (TTM)	-11836.0%	-11700.0%
ROIC (TTM)	-15673.0%	-14763.0%
Financial Health
Cash	$13M	$9M
Debt	$344K	$0
Net Cash/Debt	$13M	$9M
Current Ratio (TTM)	4.36x	4.27x
Quick Ratio (TTM)	4.11x	4.26x
Debt/Equity (TTM)	0.03x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.21	1.40
52W Performance	-20.8%	-42.9%
YTD Performance	-48.4%	-36.5%
% from 52W High	-62.2%	-63.6%
% from 52W Low	7.2%	14.4%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-27.1%	-27.7%
Earnings Yield (TTM)	-28.7%	-73.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GANX research	View RNTX research

Valuation

P/S Ratio

RNTX

0.00x

GANX

466.44x

EV/FCF

RNTX

-3.15x

GANX

-3.02x

Growth & revenue

Forward Revenue Growth

GANX

180.0%

RNTX

113.7%

Profitability & performance

Gross Margin

GANX

0.0%

RNTX

0.0%

ROE

RNTX

-15323.0%

GANX

-16158.0%

FCF Yield %

GANX

-27.1%

RNTX

-27.7%

52-Week Performance

GANX

-20.8%

RNTX

-42.9%

Detailed metrics comparison

GANX

Gain Therapeutics Inc

RNTX

Rein Therapeutics Inc

Market Cap

GANX$70M

RNTX$68M

Enterprise Value

GANX$57M

RNTX$59M

Price

GANX$1.64

RNTX$0.79

P/E Ratio

GANXN/A

RNTXN/A

P/S Ratio

GANX466.44x

RNTX0.00x

EV/Sales

GANX386.81x

RNTX0.00x

EV/EBITDA

GANX0.00x

RNTX0.00x

P/B Ratio

GANX6.61x

RNTX1.25x

P/FCF Ratio

GANXN/A

RNTXN/A

EV/FCF

GANX-3.02x

RNTX-3.15x

PEG Ratio

GANXN/A

RNTXN/A

Forward P/E (NTM)

GANXN/A

RNTXN/A

Forward P/S (NTM)

GANXN/A

RNTXN/A

Revenue (TTM)

GANX$0

RNTX$0

Revenue Growth (YoY)

GANXN/A

RNTXN/A

Forward Rev Growth

GANX180.0%

RNTX113.7%

Gross Margin (TTM)

GANX0.0%

RNTX0.0%

Operating Margin (TTM)

GANX0.0%

RNTX0.0%

EBITDA Margin (TTM)

GANX0.0%

RNTX0.0%

Net Margin (TTM)

GANX0.0%

RNTX0.0%

FCF Margin (TTM)

GANXN/A

RNTXN/A

Net Income (TTM)

GANX$-20M

RNTX$-50M

FCF (TTM)

GANX$-19M

RNTX$-19M

EPS (TTM)

GANX-$0.47

RNTX-$0.74

ROE (TTM)

GANX-16158.0%

RNTX-15323.0%

ROA (TTM)

GANX-11836.0%

RNTX-11700.0%

ROIC (TTM)

GANX-15673.0%

RNTX-14763.0%

Cash

GANX$13M

RNTX$9M

Debt

GANX$344K

RNTX$0

Net Cash/Debt

GANX$13M

RNTX$9M

Current Ratio (TTM)

GANX4.36x

RNTX4.27x

Quick Ratio (TTM)

GANX4.11x

RNTX4.26x

Debt/Equity (TTM)

GANX0.03x

RNTX0.00x

Debt/Assets (TTM)

GANX0.0%

RNTX0.0%

Interest Coverage (TTM)

GANXN/A

RNTXN/A

Net Debt/EBITDA (TTM)

GANX0.00x

RNTX0.00x

Beta

GANX0.21

RNTX1.40

52W Performance

GANX-20.8%

RNTX-42.9%

YTD Performance

GANX-48.4%

RNTX-36.5%

% from 52W High

GANX-62.2%

RNTX-63.6%

% from 52W Low

GANX7.2%

RNTX14.4%

Asset Turnover (TTM)

GANX0.01x

RNTX0.00x

FCF Yield (TTM)

GANX-27.1%

RNTX-27.7%

Earnings Yield (TTM)

GANX-28.7%

RNTX-73.3%

Dividend Yield (TTM)

GANXN/A

RNTXN/A

Rule of 40

GANX0.0

RNTX0.0

EV/GP/RG

GANXN/A

RNTXN/A

Ticker research

View GANX research View RNTX research

Metric	GANX Gain Therapeutics Inc	RNTX Rein Therapeutics Inc
Market & Valuation
Market Cap	$70M	$68M
Enterprise Value	$57M	$59M
Price	$1.64	$0.79
P/E Ratio	N/A	N/A
P/S Ratio	466.44x	0.00x
EV/Sales	386.81x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.61x	1.25x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.02x	-3.15x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	180.0%	113.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-20M	$-50M
FCF (TTM)	$-19M	$-19M
EPS (TTM)	-$0.47	-$0.74
ROE (TTM)	-16158.0%	-15323.0%
ROA (TTM)	-11836.0%	-11700.0%
ROIC (TTM)	-15673.0%	-14763.0%
Financial Health
Cash	$13M	$9M
Debt	$344K	$0
Net Cash/Debt	$13M	$9M
Current Ratio (TTM)	4.36x	4.27x
Quick Ratio (TTM)	4.11x	4.26x
Debt/Equity (TTM)	0.03x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.21	1.40
52W Performance	-20.8%	-42.9%
YTD Performance	-48.4%	-36.5%
% from 52W High	-62.2%	-63.6%
% from 52W Low	7.2%	14.4%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-27.1%	-27.7%
Earnings Yield (TTM)	-28.7%	-73.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GANX research	View RNTX research